Skip to content

A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer

A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07223463
Enrollment
160
Registered
2025-10-31
Start date
2026-08-31
Completion date
2030-08-31
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Medication Adherence

Keywords

adolescents and young adults, cancer, adherence

Brief summary

The goal of this clinical trial is to learn if a tailored intervention can help make it easier for adolescents and young adults with cancer to take their medications. The main questions the researchers are trying to answer are: * Does the tailored intervention increase adherence? * Does the tailored intervention improve quality of life? * Does the tailored intervention reduce health care utilization? The researchers will compare the tailored intervention to a uniform standard of care intervention (an intervention designed to be similar to what is currently happening in clinical care) to see if the tailored intervention works to improve adherence. Participants will: * Use an electronic pill bottle or box to store their medication * Participate in intervention sessions * Complete surveys before the intervention, after the intervention, and 6-months later

Detailed description

The proposed research includes a randomized clinical trial of a tailored adherence-promotion intervention (Tailored Program) as compared to uniform standard of care (Feedback Program) for adolescents and young adults with cancer. As part of this study, up to 160 adolescents and young adults (AYAs) with cancer will be randomized to one of these groups. Participants who enroll in this trial will be given an electronic pill bottle or box with a computer chip to store their medication. After using the electronic monitor for a few weeks to assess baseline adherence, participants who demonstrate non-adherence and have used the electronic monitor without difficulty will be asked to complete pre-treatment questionnaires. Next, participants will be randomly assigned to one of the two groups and complete their assigned program. Adolescents and young adults will continue to use the electronic monitor to store their medication until approximately a month after their program ends. After their program ends, participants will complete questionnaires at post-treatment and again about 6 months later.

Interventions

Participants will participate in 4 sessions with a coach, 1 every other week. During these sessions, the participant will work with their coach to identify a barrier to adherence they would like to target. Then, they will work with their coach to create an action plan using evidence-based behavior change techniques to address this barrier. In between sessions (on alternating weeks), the coach will check-in with a text reminder about the plan.

BEHAVIORALFeedback Program (Uniform Standard of Care)

Participants will receive weekly text messages with feedback about their adherence and guidance for requesting additional support if desired

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH
Seattle Children's Hospital
CollaboratorOTHER
University of Kansas Medical Center
CollaboratorOTHER
Columbia University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
15 Years to 24 Years
Healthy volunteers
No

Inclusion criteria

* Patient is 15.00 to 24.99 years of age * Patient is diagnosed with cancer * Patient is prescribed an oral anticancer/antitumor agent or prophylaxis

Exclusion criteria

* Patient is not fluent in English * Patient evidences significant cognitive deficits * Patient's medical status or treatment precludes participation * Patient enrolled on a medical trial requiring medication storage in a trial-provided container * Patient demonstrates greater than or equal to 95% adherence during run-in period * Patient declines to use or has difficulty using electronic adherence monitoring device during run-in

Design outcomes

Primary

MeasureTime frameDescription
Medication AdherenceThe 1-month period following the completion of one of the study programs.Each participant will be given an electronic adherence monitoring device to store their medication. An electronic adherence monitoring device is a pill bottle or box with an embedded computer chip. The computer chip records each time the device is opened. These device openings, or actuations, will be compared with the patient's prescribed medication regimen to compute their adherence (defined as the percentage of doses taken as prescribed).

Secondary

MeasureTime frameDescription
Quality of Life (Physical Health)Approximately 1 month after completing one of the study programsPROMIS (Patient-Reported Outcomes Measurement Information System) Global Physical Health 2a. Raw score range = 2-10. Higher scores = better quality of life.
Healthcare Utilization6 months post-treatmentNumber of oncology visits, lab draws, ED visits, and hospitalizations
Quality of Life (Mental Health)Approximately 1 month after completing one of the study programsPROMIS (Patient-Reported Outcomes Measurement Information System) Global Mental Health 2a. Raw score range = 2-10. Higher scores = better quality of life.

Countries

United States

Contacts

CONTACTMeghan E. McGrady, PhD
Meghan.McGrady@cchmc.org513-803-8044
PRINCIPAL_INVESTIGATORMeghan E. McGrady, PhD

Children's Hospital Medical Center, Cincinnati

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026